Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology Annual Meeting

Corvus制药公司将在美国血液学协会年会上展示1/1b期试验的临床数据

2019-11-08 17:42:47 BioSpace

本文共822个字,阅读需3分钟

Corvus Pharmaceuticals, Inc,  , a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it will present preclinical and early clinical data from its Phase 1/1b clinical trial of CPI-818 at the American Society of Hematology 61st Annual Meeting 2019 in Orlando, Florida, taking place December 7-10, 2019. Corvus will present data on CPI-818 in two poster sessions: Poster Presentations: About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and with pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522 LLea@corvuspharma.com MEDIA CONTACT: Sheryl Seapy W2O pure +1 213-262-9390 sseapy@purecommunications.com
Corvus Pharmaceuticals , Inc .,一家临床阶段的生物制药公司,专注于开发和商业化具有生物标志物患者富集选择的精确靶向肿瘤治疗,今天宣布,它将在2019年12月7-10日于弗洛里达州奥兰多召开的美国血液学会第61届年会上展示 CPI-818的1b 期临床试验的临床前和早期临床数据。 Corvus 将在两次海报会议上介绍 CPI-818的数据: 海报介绍: 关于 Corvus 制药公司 Corvus Pharmaceuticals 是一家临床阶段的生物制药公司,专注于精确靶向肿瘤治疗的开发和商业化。Corvus 的主要产品候选药物是 ciprodenant ( CPI-444),一种 A2A 受体的小分子抑制剂,和 CPI-006,一种针对 CD73的人源化单克隆抗体,具有免疫调节活性和腺苷生产的阻断。这些候选人正在进行中的第一阶段和第二阶段临床试验的患者范围广泛的晚期实体肿瘤。在一次连续的扩大队列试验中,正在对西弗丹宁进行评估,该试验考察了西弗丹宁作为单一药物的活性,并结合抗 PD-L1抗体。CPI-006在多中心1/1b 期临床试验中作为单一药物,联合 ciprodenant 和 pembrolizumab 进行评估。公司的第三个临床项目 CPI-818是一种口服的小分子药物,已被证明有选择性地抑制 ITK ,在几种 T 细胞淋巴瘤患者中正在进行多中心1/1b 期临床试验。有关详细信息,请访问:\160; www.corvussparma.com 。 投资者联系人: Leiv Lea 首席财务官 Corvus Pharmaceuticals , Inc . 650-900-4522 LLea @ corvussparma.com MEDIA Contact : Sheryl Seapy W2O 纯 +1213-262-9390 sseapy @ purecommunications.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文